Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact

Blood. 2000 Oct 15;96(8):2673-81.

Abstract

Chemokines are mediators in inflammatory and autoimmune disorders. Aminoterminal truncation of chemokines results in altered specific activities and receptor recognition patterns. Truncated forms of the CXC chemokine interleukin (IL)-8 are more active than full-length IL-8 (1-77), provided the Glu-Leu-Arg (ELR) motif remains intact. Here, a positive feedback loop is demonstrated between gelatinase B, a major secreted matrix metalloproteinase (MMP-9) from neutrophils, and IL-8, the prototype chemokine active on neutrophils. Natural human neutrophil progelatinase B was purified to homogeneity and activated by stromelysin-1. Gelatinase B truncated IL-8(1-77) into IL-8(7-77), resulting in a 10- to 27-fold higher potency in neutrophil activation, as measured by the increase in intracellular Ca(++) concentration, secretion of gelatinase B, and neutrophil chemotaxis. This potentiation correlated with enhanced binding to neutrophils and increased signaling through CXC chemokine receptor-1 (CXCR1), but it was significantly less pronounced on a CXCR2-expressing cell line. Three other CXC chemokines-connective tissue-activating peptide-III (CTAP-III), platelet factor-4 (PF-4), and GRO-alpha-were degraded by gelatinase B. In contrast, the CC chemokines RANTES and monocyte chemotactic protein-2 (MCP-2) were not digested by this enzyme. The observation of differing effects of neutrophil gelatinase B on the proteolysis of IL-8 versus other CXC chemokines and on CXC receptor usage by processed IL-8 yielded insights into the relative activities of chemokines. This led to a better understanding of regulator (IL-8) and effector molecules (gelatinase B) of neutrophils and of mechanisms underlying leukocytosis, shock syndromes, and stem cell mobilization by IL-8. (Blood. 2000;96:2673-2681)

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Blood Coagulation Factors / metabolism
  • Calcium Signaling / drug effects
  • Chemokine CCL5 / analysis
  • Chemokine CCL8
  • Chemokine CXCL1
  • Chemokines / metabolism*
  • Chemokines, CXC*
  • Chemotactic Factors / metabolism
  • Drug Synergism
  • Enzyme Activation / drug effects
  • Enzyme Precursors / metabolism
  • Feedback
  • Growth Substances / metabolism
  • Humans
  • Intercellular Signaling Peptides and Proteins*
  • Interleukin-8 / pharmacology*
  • Matrix Metalloproteinase 3 / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • Matrix Metalloproteinase 9 / pharmacology*
  • Molecular Sequence Data
  • Monocyte Chemoattractant Proteins / analysis
  • Neutrophils / enzymology*
  • Peptide Fragments / pharmacology
  • Peptides*
  • Platelet Factor 4 / metabolism
  • Protein Processing, Post-Translational*
  • Receptors, Interleukin-8A / physiology
  • Substrate Specificity

Substances

  • Blood Coagulation Factors
  • CCL8 protein, human
  • CXCL1 protein, human
  • Chemokine CCL5
  • Chemokine CCL8
  • Chemokine CXCL1
  • Chemokines
  • Chemokines, CXC
  • Chemotactic Factors
  • Enzyme Precursors
  • Growth Substances
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-8
  • Monocyte Chemoattractant Proteins
  • Peptide Fragments
  • Peptides
  • Receptors, Interleukin-8A
  • Platelet Factor 4
  • connective tissue-activating peptide
  • low affinity platelet factor 4
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 9